Replies to post #2238 on Gilead Sciences Inc (GILD)

[north40000]

I could not see slides either from that link. I did hear, I think correctly, that GILD's estimated share of U.S. HCV market >90%.

Q&A: Treating HCV patients earlier is encouraged.
PBM rethinking is possible in near future in light of recent events with other companies.

Market volatility has not changed M&A outlook---when a deal is appropriate, it will get done.